# Tenax Therapeutics Inc. (TENX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $414M  
**Price:** $10.55 (-1.68%)

> Tenax Therapeutics Inc. is a pharmaceutical company focused on developing and commercializing products for the critical care market. The primary function of Tenax Therapeutics is to develop clinical-stage treatments in areas such as cardiopulmonary diseases. One of the notable features of the company is its dedication to researching and advancing therapies to address significant unmet medical needs, particularly through innovative drug development. Tenax Therapeutics has been part of the critical care segment, working on potential treatments that could have a substantial impact on patients with severe cardiovascular and pulmonary conditions. The firm's activities in novel drug formulations and clinical trials contribute to its role in the biopharmaceutical landscape, aiming to bring new hope and innovative therapies to markets with limited options. Based in the United States, Tenax Therapeutics continues to push forward in the field of healthcare, leveraging scientific research and pharmaceutical advancements to impact the lives of patients and the broader healthcare community significantly.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | — | — | -$56M | -$53M | $-1.34 |
| 2024 | — | — | -$19M | -$18M | $-1.15 |
| 2016 | — | — | -$53M | -$44M | — |
| 2015 | $49,286 | — | -$15M | -$14M | $-0.50 |
| 2014 | $158,926 | -$104,069 | -$17M | -$20M | $-2.71 |
| 2013 | $1M | $49,572 | -$5M | -$9M | $-6.68 |
| 2012 | $363,781 | $49,266 | -$8M | -$16M | $-14.07 |
| 2011 | $103,167 | $103,167 | $11M | $10M | $-0.45 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $104M | $7M | $97M | $98M | — |
| 2024 | $97M | $5M | $92M | $95M | — |
| 2016 | $23M | $6M | $17M | $10M | — |
| 2015 | $83M | $12M | $70M | $8M | — |
| 2014 | $93M | $11M | $83M | $58M | — |
| 2013 | $3M | $5M | -$2M | $783,528 | — |
| 2012 | $4M | $4M | -$346,046 | $2M | — |
| 2011 | $3M | $7M | -$4M | $951,944 | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$36M | — | — |
| 2024 | -$15M | — | — |
| 2023 | -$6M | — | — |
| 2022 | -$11M | $2,323 | -$11M |
| 2021 | -$11M | $5,252 | -$11M |
| 2020 | -$9M | $3,490 | -$9M |
| 2019 | -$8M | $3,574 | -$8M |
| 2018 | -$5M | $7,595 | -$6M |
| 2017 | -$12M | $4,537 | -$12M |
| 2016 | -$16M | $2,884 | -$16M |
| 2015 | -$10M | $4,234 | -$10M |
| 2014 | -$9M | $9,804 | -$9M |
| 2013 | -$5M | $17,199 | -$5M |
| 2012 | -$8M | $17,652 | -$8M |
| 2011 | -$8M | $240,824 | -$9M |

Source: [CompaniesByCap](https://companiesbycap.com/company/TENX)